Trading Summary - September 3. More excellent

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
305
Trading Summary - September 3.

More excellent opportunities for adding in the .4700 > .6000 range during another status quo day whilst top traders were still busy with multiple runners on the Watch List.

Again, I and at least one other trader succeeded in continuing to deny reloads on the bid to the basher / flippers on iHub by outbidding them with hidden bids to catch paint downs.

Traders failed to hit the artificially low ask which had retreated to .5400 - there was only 2,500 there - so the scammers again walked down to .4800 then .4700.

The basher / scammers still appear to be trying to dupe impatient people to trade into their large waiting bids at .4000 which now total a massive 52K.

There is still almost nothing actually available under the previous high of .7700 - with the first artificially low ask constantly moving between .4700 and .6000.

When the CEO is ready to move the stock up - or the top traders in it decide to - or the company gives a provisional estimate of the value of the first hemp crop when harvested, $EVSV will be back at .7700 in a few individual seconds and on its way into the $1 > $2 range.

Overall, another 3,873 shares were bought today - again all at levels that will make 150% > 200% profit fairly easily at some point in 2019.

There are now less than 2 weeks until the first hemp crop is harvested.

The following items below the line unchanged since the last Trading Summary:

We now have a confirmed target date of mid-September for the harvest of the first hemp crop at the first of several planned production sites.

The 2019 Q2 was filed on August 7, 2019 in a timely manner (see separate post) and gave a very good description of the holding company $EVSV's current portfolio and partnerships (unable to copy - read in filing).

The top traders in $EVSV aren't going to waste out time nickel and diming trying to fill on the bid when there is so much else going on with Watch List stocks to attend to daily. We will just take out everything on the ask under 1.000 at a time of our choosing.

Top traders who are the movers and shakers of $EVSV will continue the transfer of more of their profits from other trades into $EVSV up until the first hemp crop revenues come out.

Don't expect much to be made available under 1.000.

For those who have been following the "trading successfully through a r/s strategy" since the warning day on January 24, even those who failed to buy in the .4000 > .7150 range over the past 6+ months still have a chance to buy more shares in the .7700 > 1.600 range before the pre-r/s shares come in to play.

The pre-r/s shares from legacy holders aren't going to be significant in number under 2.000 - as is well known to those who were trading in the .0007 > .0011 range pre-r/s for 2 reasons:

- Many amateur iHub mentality traders needlessly sell for a loss as a matter of course as soon as warning is given of a r/s - reducing drastically the number of shares at the former flipper log jam price (which was 1.4000 > 2.000 in "new money".

- Those that kept their shares have had them divided by 2000 - so insignificant in the grand scheme of things bearing in mind we are looking at NASDAQ price levels for $EVSV now.

On July 29, 2019 the Transfer Agent updated the Verified Company Profile early to confirm both no dilution of the Common Unrestricted shares and the previously announced 50,000 share reduction - with more known to be coming and a possible share buyback by the company as well.





Enviro-Serv, Inc. (EVSV) Stock Research Links

EVSV Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading